Literature DB >> 17460285

Clearance of intravitreal voriconazole.

Ying-Cheng Shen1, Mei-Yen Wang, Chun-Yuan Wang, Tsun-Chung Tsai, Hin-Yeung Tsai, Yi-Fen Lee, Li-Chen Wei.   

Abstract

UNLABELLED: Purpose To investigate the elimination rate of voriconazole after intravitreal injection in rabbits.
METHODS: Intravitreal injections of 35 microg/0.1 mL voriconazole were administered to rabbits. Vitreous and aqueous humor levels of voriconazole were determined at selected time intervals (1, 2, 4, 8, 16, 24, and 48 hours), and the in vitreous half-life was calculated. Four to six eyes per time point after injection were enucleated and immediately stored at -80 degrees C. Aqueous humor samples were withdrawn before enucleation, and vitreous samples were obtained from ocular dissection and isolation at various time intervals. Voriconazole concentrations in vitreous and aqueous humor were assayed with high-performance liquid chromatography (HPLC).
RESULTS: The concentration of intravitreal voriconazole at various time points exhibited exponential decay with a half-life of 2.5 hours. The mean vitreous concentration was 18.912 +/- 2.058 microg/mL 1 hour after intravitreal injection; this declined to 0.292 +/- 0.090 microg/mL at 16 hours. The mean aqueous concentration was much lower and showed a decline from 0.240 +/- 0.051 microg/mL at 1 hour to undetectable levels 8 hours after injection.
CONCLUSIONS: Vitreous concentrations achieved during the first 8 hours were greater than the previously reported minimum inhibitory concentrations (MICs) of organisms most involved in fungal endophthalmitis. A rapid decline of intravitreal concentration suggests that supplementation of intraocular voriconazole to maintain therapeutic levels may therefore be required in clinical settings. Further studies are needed to determine the elimination rate of voriconazole after intravitreal injection in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460285     DOI: 10.1167/iovs.06-1362

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment.

Authors:  Nahid Haghjou; Mohammad J Abdekhodaie; Yu-Ling Cheng
Journal:  Pharm Res       Date:  2012-10-02       Impact factor: 4.200

3.  Cytotoxicity of voriconazole on cultured human corneal endothelial cells.

Authors:  Sang Beom Han; Young Joo Shin; Joon Young Hyon; Won Ryang Wee
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

4.  Persistently Vitreous Culture-Positive Exogenous Fungal Endophthalmitis.

Authors:  Ella H Leung; Ajay E Kuriyan; Harry W Flynn; Nidhi Relhan; Laura C Huang; Darlene Miller
Journal:  Am J Ophthalmol       Date:  2016-09-16       Impact factor: 5.258

5.  Intravitreal voriconazole as primary treatment for endogenous Aspergillus endophthalmitis.

Authors:  Tiago Bravo Ferreira; Fernanda Vaz; Antonio Rodrigues; Sofia Donato
Journal:  BMJ Case Rep       Date:  2009-05-21

6.  Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis.

Authors:  Jeong Hun Bae; Sung Chul Lee
Journal:  Jpn J Ophthalmol       Date:  2015-07-28       Impact factor: 2.447

7.  Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Authors:  Chandrasekar Durairaj; Jaymin C Shah; Shruti Senapati; Uday B Kompella
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

8.  Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.

Authors:  Jeeyun Ahn; Hyuncheol Kim; Se Joon Woo; Ji Hyun Park; Sunyoung Park; Duck Jin Hwang; Kyu Hyung Park
Journal:  J Ocul Pharmacol Ther       Date:  2013-06-04       Impact factor: 2.671

9.  Pharmacokinetics and safety of intravitreal caspofungin.

Authors:  Ying-Cheng Shen; Chiao-Ying Liang; Chun-Yuan Wang; Keng-Hung Lin; Min-Yen Hsu; Hon-Leung Yuen; Li-Chen Wei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

10.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.